Immunity enhancing agent for cancer by Allergin-1 antagonist
US11638744B2 · kind B2 · utility
0Cited by
4References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 2, 2016 |
| Grant date | May 2, 2023 |
| Priority date | — |
| Expiry date | Sep 2, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/75
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method for suppression of progress of, suppression of recurrence of and/or treatment of cancer, by administering an Allergin-1 antagonist in a therapy of a cancer patient with insufficient therapeutic efficacy by a tumor immunotherapeutic agent, or a cancer therapy in combination with an anti-cancer drug.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.